Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bristol-Myers Squibb announces negative Erbitux trial results

Bristol-Myers Squibb announces negative Erbitux trial results

11th April 2007

Bristol-Myers Squibb and ImClone Systems have announced negative results of a phase III clinical trial of Erbitux (cetuximab) plus chemotherapy gemcitabine as a treatment for locally advanced unresectable or metastatic pancreatic cancer.

The study conducted by cancer centre network the Southwest Oncology Group (Swog) reveals that the compound did not meet its primary endpoint of increasing overall survival in patients.

Swog, ImClone Systems and Bristol-Myers Squibb will now join forces to fully assess the results of the trial that involved 700 pancreatic cancer patients in the first-line treatment setting.

Martin Birkhofer, vice-president of oncology global medical affairs at Bristol-Myers Squibb, said: “Pancreatic cancer is a devastating disease with few effective treatment options and it is unfortunate that the use of Erbitux in this trial has not demonstrated the benefit it has shown in other tumours.”

He added that the firm was looking to investigate this data in further detail and would continue to assess the potential benefits of the compound for cancer patients.

Last week, Bristol-Myers Squibb and ImClone Systems announced positive results of a phase III clinical trial investigating the use of Erbitux in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.